ARDS - Aridis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
1,000
1,022
Operating expenses
Research development
26,482
25,923
37,936
16,956
24,083
Selling general and administrative
7,508
7,161
7,310
6,445
6,026
Total operating expenses
31,125
29,993
43,711
23,401
30,109
Operating income or loss
-31,125
-29,993
-43,711
-22,401
-29,087
Total other income/expenses net
-1,155
-257
763
-9
-951
Income before tax
-32,794
-30,371
-43,193
-22,333
-29,681
Income from continuing operations
-32,794
-30,371
-43,193
-22,333
-29,681
Net income
-32,794
-30,371
-43,193
-22,333
-29,681
Net income available to common shareholders
-32,794
-30,371
-47,320
-22,333
-29,681
Basic EPS
-
-
-3.85
-2.44
-3.51
Diluted EPS
-
-
-3.85
-2.44
-3.51
Basic average shares
-
-
12,292
9,169
8,458
Diluted average shares
-
-
12,292
9,169
8,458
EBITDA
-
-29,506
-43,711
-22,401
-29,087